The Texas A&M University System and a Texas company have been awarded a $40 million grant from the U.S. Department of Defense to develop vaccines made from tobacco rather than the antiquated egg-based technology.

Influenza Vaccine

SARANAC LAKE, N.Y. — The Trudeau Institute will receive an additional $1.6 million for its work with the U.S. Navy to research the impact and efficacy of combining influenza vaccinations with antiviral drugs.

SAN DIEGO — Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases — tuberculosis, malaria and dengue virus.

Dr. Michael Gale Jr.

SEATTLE— Kineta Inc. has announced that it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases to develop novel vaccine adjuvants (agents that help boost the immune system).

Smallpox

ALACHUA, Fla. — Nanotherapeutics Inc. has been awarded a $30.9 million, five-year contract from the National Institute of Allergy and Infectious Diseases to develop an inhaled version of the injectable antiviral drug cidofovir.

Dr. Tachi Yamada

ARUSHA, Tanzania — The Bill & Melinda Gates Foundation announced 76 grants of $100,000 each to pursue bold ideas for transforming health in developing countries.

Emergent BioSolutions Inc. announced in September 2009 that it received a grant from the National Institute of Allergy and Infectious Diseases to continue the development of an advanced anthrax vaccine candidates known as dmPA7909.

National Institute of Allergy and Infectious Disease

Emergent BioSolutions Inc. announced that it has secured two grants totaling more than $4.5 million from the NIAID to fund the continued development of the company’s recombinant botulinum (rBOT) and next-generation anthrax vaccine (NGAV) candidates.

Anthrax

Emergent BioSolutions announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases totaling $3.8 million to support the development of the anthrax immune globulin (AIG) therapeutic product.